Table 7.
Significant findings after multiple regression analyses of covariates with recovery until hospital discharge, stratified by median value.
| Overall patients(n = 93). P value. | Asthma and allergy patients (n = 21). P value. | Other patients(n = 72). P value. | |
|---|---|---|---|
| Age | 0.002 | n.s. | 0.013 |
| Comorbidity excluding asthma or allergy | 0.015 | n.s. | n.s. |
| Antecedents of dyslipidemia | n.s. | 0.025 | n.s. |
| Antecedents of hypertension | n.s. | n.s. | 0.030 |
| Antecedents of prothrombotic disorders | n.s. | 0.010 | 0.050 |
| Drugs used in allergic diseases | |||
| Inhaled corticosteroids | 0.051 | 0.033 | 0.005 |
| Drugs used in cardiovascular diseases | |||
| Angiotensin-II-receptor antagonists | n.s. | 0.043 | n.s. |
| Symptoms | |||
| Musculoskeletal pain | 0.012 | n.s. | 0.021 |
| Laboratory and clinical findings | |||
| Oxygen saturation | 0.007 | n.s. | 0.006 |
| Leukocytes per microliter | n.s | n.s | 0.034 |
| Eosinophils per microliter | 0.006 | n.s. | n.s. |
| D-dimer, ng/mL | 0.006 | n.s. | n.s |
| Ferritin, ng/mL | n.s | n.s | 0.002 |
| Radiological findings | |||
| No radiological findings | 0.005 | n.s. | 0.002 |
| Drug therapy after admission | |||
| Lopinavir plus ritonavir | 0.032 | n.s. | n.s. |
| Corticosteroids | 0.001 | 0.033 | 0.001 |